ReviewFrontiers in pharmacology2025
Recent advances in gut microbiota-based nanotherapies for cancer treatment.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of gut microbiota on carcinogenesis and progression has been demonstrated and arisen wide attention. Notably, specific microbial communities demonstrate dual therapeutic potential in enhancing anti-tumor treatment efficacy and mitigating chemotherapy-induced adverse effects, positioning microbial intervention as an innovative paradigm in oncology therapeutics. However, the clinical application of oral delivery of free-living gut microbiota faces significant challenges due to their inherent instability and premature clearance within the gastrointestinal tract. This biological limitation underscores the critical need for advanced delivery systems capable of preserving microbial viability and achieving targeted delivery. Nanotherapy, renowned for their precise targeting capabilities, exceptional biocompatibility, and enhanced pharmacokinetic profiles, have demonstrated transformative potential across biomedical applications, with several formulations already advancing to clinical implementation. Remarkably, current research on the delivery of gut microbiota for cancer treatment via nanotechnology remains limited and lacks comprehensive summarization. Therefore, this review systematically summarized recent advancements in gut microbiota-mediated nanotherapeutic strategies against cancer, proposing novel conceptual frameworks for synergistic microbiota-nanotherapy integration in cancer interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.